These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 32295861)
1. Risk-Based Approach for Analytical Comparability and Comparability Protocols. Iyer KR; Lequeux I PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861 [TBL] [Abstract][Full Text] [Related]
2. Characterizing biological products and assessing comparability following manufacturing changes. Chirino AJ; Mire-Sluis A Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163 [TBL] [Abstract][Full Text] [Related]
3. Quality, safety and efficacy of follow-on biologics in Japan. Yamaguchi T; Arato T Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377 [TBL] [Abstract][Full Text] [Related]
4. Comparability and biosimilarity: considerations for the healthcare provider. Lee JF; Litten JB; Grampp G Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391 [TBL] [Abstract][Full Text] [Related]
5. Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs. Colbert A; Umble-Romero A; Prokop S; Chow VF; Wong T; DeSimone D; Zhou L; Pederson S MAbs; 2014; 6(5):1178-89. PubMed ID: 25517303 [TBL] [Abstract][Full Text] [Related]
6. Industry One-Voice-of-Quality (1VQ) Solutions: Effective Management of Post-Approval Changes in the Pharmaceutical Quality System (PQS)-through Enhanced Science and Risk-Based Approaches. Ramnarine E; Vinther A; Bruhin K; Tovar C; Colao M PDA J Pharm Sci Technol; 2020; 74(4):456-467. PubMed ID: 32467177 [TBL] [Abstract][Full Text] [Related]
7. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability. Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407 [TBL] [Abstract][Full Text] [Related]
8. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832 [TBL] [Abstract][Full Text] [Related]
9. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products. Kwon O; Joung J; Park Y; Kim CW; Hong SH Biologicals; 2017 Jul; 48():101-108. PubMed ID: 28495312 [TBL] [Abstract][Full Text] [Related]
10. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products. Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108 [TBL] [Abstract][Full Text] [Related]
11. A practical discussion of risk management for manufacturing of pharmaceutical products. Mollah AH; Baseman HS; Long M; Rathore AS PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348 [TBL] [Abstract][Full Text] [Related]
13. The process defines the product: what really matters in biosimilar design and production? Vulto AG; Jaquez OA Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv14-iv29. PubMed ID: 28903544 [TBL] [Abstract][Full Text] [Related]
14. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management. Vinther A; Ramnarine E PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505 [TBL] [Abstract][Full Text] [Related]
16. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855 [TBL] [Abstract][Full Text] [Related]
17. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design. Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164 [TBL] [Abstract][Full Text] [Related]
18. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization World Health Organ Tech Rep Ser; 2014; (986):1-387, back cover. PubMed ID: 24964711 [TBL] [Abstract][Full Text] [Related]
19. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics. Ishii-Watabe A; Hirose A; Katori N; Hashii N; Arai S; Awatsu H; Eiza A; Hara Y; Hattori H; Inoue T; Isono T; Iwakura M; Kajihara D; Kasahara N; Matsuda H; Murakami S; Nakagawa T; Okumura T; Omasa T; Takuma S; Terashima I; Tsukahara M; Tsutsui M; Yano T; Kawasaki N AAPS PharmSciTech; 2015 Oct; 16(5):993-1001. PubMed ID: 26288941 [TBL] [Abstract][Full Text] [Related]
20. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective. Zhuang Y; Chen D; Sharma A; Xu Z AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]